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LETTER TO THE EDITOR
Reply to the letter from Dr Remvikos
Sir - We are grateful for the opportunity to reply to Dr
Remvikos' comments upon our paper. He states that the title
of the paper does not accurately reflect the conclusions of the
study reported therein. In our hands, neither DNA ploidy or
S phase fraction showed independent prognostic significance.
This is what the title says. The fact that this could be due to a
type II statistical error does not alter this fact. Nor does the
presence of such prognostic power for S phase fraction in the
hands of others mean that this factor is worth pursuing. The
size of the survival difference between groups defined by the
median is not large in any study (of the order of 10% at 10
years), and our data indicate that the assignation of SPF is
not as accurate as previous reports have suggested.
The statement that the data on thymidine labelling of
breast cancers appears to be more homogeneous (than that
from flow cytometry presumably) is difficult to interpret.
Does this mean that the labelling index observed by different
groups is similar? This is not borne out if we compare the
overall median value for TLI as reported by the two groups
with greatest experience, Meyer (5.2%) and Silvestrini
(2.8%).
Speculations as to the biological mechanism by which any
particular factor might exert a prognostic effect has no bear-
ing upon the importance of that factor. Thus despite the
information as to the potential significance of variation of
DNA content presented by Dr Remvikos, he agrees that
DNA ploidy is not of prognostic value, thereby rendering the
information irrelevant to this argument. It is indeed very
appealing to argue that the proliferative characteristics of
tumours will help predict the response to therapy, but given
the small size of the observed survival difference between
groups defined by SPF, and the inherent uncertainty of the
measurement itself, we should remain sceptical about this
until more substantive clinical data are presented. As Dr
Remvikos admits, SPF has been embraced overenthusias-
tically by some authors. We feel that it is important to
provide a counterbalance to this. This is the central point at
issue, and it is the one correctly addressed by Dr Miller.
Yours etc,
P.D. Stanton,
T.G. Cooke,
Department of Surgery,
Royal Infirmary,
Glasgow G31 2ER.
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